Safety and Efficacy of Lorcaserin: A Combined Analysis of the BLOOM and BLOSSOM Trials

References

• . Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity among adults: United States, 2011–2012. NCHS Data Brief. 2013;(131):1–8
   Google Scholar
• . Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74–86
   PubMed Web of Science ®Google Scholar
• . Wadden TA, Volger S, Tsai AG,. POWER-UP Research Group. Managing obesity in primary care practice: an overview and perspective from the POWER-UP study. Int J Obes (Lond). 2013;37( Suppl 1):S3–S11
   PubMedGoogle Scholar
• . Sumithran P, Prendergast LA, Delbridge E,. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597–1604
   PubMed Web of Science ®Google Scholar
• . Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest. 2003;111(9):1409–1421
   PubMed Web of Science ®Google Scholar
• . Garfield AS, Heisler LK. Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009;587(Pt 1):49-–60
   PubMed Web of Science ®Google Scholar
• . Lam DD, Przydzial MJ, Ridley SH,. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology. 2008;149(3):1323–1328
   Google Scholar
• . Halford JC, Boyland EJ, Lawton CL, Blundell JE, Harrold JA. Serotonergic anti-obesity agents: past experience and future prospects. Drugs. 2011;71(17):2247–2255
   PubMed Web of Science ®Google Scholar
• . Thomsen WJ, Grottick AJ, Menzaghi F,. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325(2):577–587
   PubMed Web of Science ®Google Scholar
• . Phelan S, Nallari M, Darroch FE, Wing RR. What do physicians recommend to their overweight and obese patients? J Am Board Fam Med. 2009;22(2):115–122
   Google Scholar
• . Salinas GD, Glauser TA, Williamson JC, Rao G, Abdolrasulnia M. Primary care physician attitudes and practice patterns in the management of obese adults: results from a national survey. Postgrad Med. 2011;123(5):214–219
   PubMed Web of Science ®Google Scholar
• . Heisler LK, Jobst EE, Sutton GM,. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron. 2006;51(2):239–249
   PubMed Web of Science ®Google Scholar
• . Martin CK, Redman LM, Zhang J,. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2011;96(3):837–845
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. BELVIQ (lorcaserin hydrochloride) Highlights of Prescribing Information. https://www.belviq.com/pdf/Belviq_Prescribing_information.pdf. Revised August 2012. Accessed September 10, 2014
   Google Scholar
• . Smith SR, Weissman NJ, Anderson CM,. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–256
   PubMed Web of Science ®Google Scholar
• . Fidler MC, Sanchez M, Raether B,. BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–3077
   PubMed Web of Science ®Google Scholar
• . Weissman NJ, Sanchez M, Koch GG, Smith SR, Shanahan WR, Anderson CM. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013;6(4):560–567
   PubMed Web of Science ®Google Scholar
• . O'Neil PM, Smith SR, Weissman NJ,. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426–1436
   PubMed Web of Science ®Google Scholar
• . Apovian CM, Aronne L, Rubino D,. COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935–943
   PubMed Web of Science ®Google Scholar
• . Greenway FL, Fujioka K, Plodkowski RA,. COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2010;376(9741):594, and Lancet. 2010;376(9750):1392]. Lancet. 2010;376(9741):595–605
   Google Scholar
• . Dalle Grave R, Calugi S, Molinari E,. QUOVADIS Study Group. Weight loss expectations in obese patients and treatment attrition: an observational multicenter study. Obes Res. 2005;13(11):1961–1969
   PubMedGoogle Scholar
• . Jensen MD, Ryan DH, Apovian CM,. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102-–S138
   Google Scholar
• . Knowler WC, Barrett-Connor E, Fowler SE,. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403
   PubMed Web of Science ®Google Scholar
• . Tuomilehto J, Lindström J, Eriksson JG,. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–1350
   PubMed Web of Science ®Google Scholar
• . Grimm RH Jr, Cohen JD, Smith WM, Falvo-Gerard L, Neaton JD. Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT). Six-year intervention results for men in special intervention and usual care groups. Arch Intern Med. 1985;145(7):1191–1199
   Google Scholar
• . Wassertheil-Smoller S, Blaufox MD, Oberman AS, Langford HG, Davis BR, Wylie-Rosett J. The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Intern Med. 1992;152(1):131–136
   Google Scholar
• . Whelton PK, Appel LJ, Espeland MA,. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group [published correction appears in JAMA. 1998;279(24):1954]. JAMA. 1998;279(11):839–846
   PubMed Web of Science ®Google Scholar
• . Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126(10):1301–1313
   PubMed Web of Science ®Google Scholar
• . Lichtenstein AH. Thematic review series: patient-oriented research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns. J Lipid Res. 2006;47(8):1661–1667
   Google Scholar
• . Nordmann AJ, Nordmann A, Briel M,. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166(3):285–293
   PubMed Web of Science ®Google Scholar
• . Wood RJ, Volek JS, Liu Y, Shachter NS, Contois JH, Fernandez ML. Carbohydrate restriction alters lipoprotein metabolism by modifying VLDL, LDL, and HDL subfraction distribution and size in overweight men. J Nutr. 2006;136(2):384–389
   Google Scholar
• . Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA. 2000;283(13):1703–1709
   PubMed Web of Science ®Google Scholar
• . James WP, Caterson ID, Coutinho W,. SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–917
   PubMed Web of Science ®Google Scholar
• . Foster GD, Wadden TA, Makris AP,. Primary care physicians' attitudes about obesity and its treatment. Obes Res. 2003;11(10):1168–1177
   PubMedGoogle Scholar
• . Heilbronn LK, de Jonge L, Frisard MI,. Pennington CALERIE Team. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial [published correction appears in JAMA. 2006;295(21):2482]. JAMA. 2006;295(13):1539–1548
   PubMed Web of Science ®Google Scholar
• . Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial [published correction appears in JAMA. 2006;295(11):1252]. JAMA. 2006;295(7):761–775
   PubMed Web of Science ®Google Scholar
• . Fabricatore AN, Wadden TA, Moore RH,. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev. 2009;10(3):333–341
   PubMed Web of Science ®Google Scholar